ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Genotropin Study Assessing Use of Injection Pen

ClinicalTrials.gov ID: NCT00965484

Public ClinicalTrials.gov record NCT00965484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-Label Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Injection Pen

Study identification

NCT ID
NCT00965484
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • New Genotropin Pen Device

Device

Eligibility (public fields only)

Age range
8 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2009
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009
Last update posted
Jan 27, 2011

2009 – 2010

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site San Diego California 92123-4282
Pfizer Investigational Site Greenwood Village Colorado 80111
Pfizer Investigational Site Gainesville Florida 32608
Pfizer Investigational Site Gainesville Florida 32610
Pfizer Investigational Site Tallahassee Florida 32308
Pfizer Investigational Site Indianapolis Indiana 46202
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Baltimore Maryland 21229
Pfizer Investigational Site Southaven Mississippi 38671
Pfizer Investigational Site Kansas City Missouri 64108
Pfizer Investigational Site Morristown New Jersey 07962
Pfizer Investigational Site Akron Ohio 44308
Pfizer Investigational Site Columbus Ohio 43205
Pfizer Investigational Site Philadelphia Pennsylvania 19107
Pfizer Investigational Site Pittsburgh Pennsylvania 15218
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Florence South Carolina 29506
Pfizer Investigational Site Memphis Tennessee 38105
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Dallas Texas 75230
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site Fort Worth Texas 76104
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00965484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2011 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00965484 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →